Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

Who May Qualify: - Ability to provide written willing to sign a consent form prior to participation in the study. - Male or female subjects aged ≥18 years at the time the willing to sign a consent form form is signed. - Diagnosis of EGPA: Subjects who have been diagnosed with EGPA based on the history or presence of eosinophilia plus at least a history or presence of 2 of additional features of EGPA. - Subjects receive background OGC dose of ≥7.5 mg/day with or without stable treatment with Mepolizumab/Benralizumab. - Use of adequate contraception. - Other inclusion criteria may apply. Who Should NOT Join This Trial: - Current diagnosis of either granulomatosis with polyangiitis or microscopic polyangiitis - Imminently life-threatening EGPA at the time of screening. - History or presence of any form of cancer within 5 years prior to screening. - Serious liver, renal, blood, or psychiatric disease - Severe or clinically significant cardiovascular disease uncontrolled with standard treatment - Active systemic infections (including TB, pneumonia, Pneumocystis pneumonia, sepsis, and opportunistic infections) - Parasitic infection: Subjects with a known parasitic infestation within 6 months prior to screening. - HIV positive status - Active hepatitis due to hepatitis B virus or hepatitis C virus - Known history or presence of venous thromboembolism/venous thrombotic events (deep vein thrombosis and/or pulmonary embolus) - laboratory parameter exclusions: 1. Estimated glomerular filtration rate of \<30 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equations 2. WBC count \<4 × 109/L 3. Absolute lymphocyte count \<500 cells/mm3 4. Absolute neutrophil count \<1000 cells/mm3 5. Platelet count \<120,000/mm3 6. Hemoglobin \<8 g/dL (\<80 g/L) - Subjects who are pregnant, breastfeeding, or planning to become pregnant during the time of study participation - History of clinically significant drug or alcohol abuse within the last 6 months ...See full criteria on ClinicalTrials.gov Always talk to your doctor about whether this trial is right for you.